optohive’s Post

What sets a truly disruptive startup apart? 💡 Its ability to be recognized as one of the most promising in Europe during its early stages is definitely a strong indicator of success!! 🚀 🏆 At S2 Xpeed, we are thrilled to share that Time is Brain has been featured by Sifted in their latest Medtech Briefing as one of the early-stage startups to watch in Europe. This recognition, awarded by one of the most influential media brands in the European startup community and backed by the Financial Times, not only acknowledges the incredible work Time is Brain is doing in the field of medical technology, but also underscores the impact we aim to drive through our acceleration programs. Time is Brain’s advancements in stroke diagnosis and improved patient care are a clear example of how innovation can transform key sectors like healthcare. 💡 And this is just one example of the immense potential of the startups participating in our programs. We are proud to see how, step by step, the companies we accelerate are making a real difference in their respective fields. Thank you to Sifted for recognizing this mission, and to Time is Brain for being a shining example of what it means to accelerate innovation🚀 Alicia Martínez Piñeiro, Blas Diaz, Gisela Ruiz Vega #StartupsToWatch #medtech #innovation #corporateventuring #S2Xpeed

#fundingalert 💼Company: Limbic 💰Funding: $14Million ⚡Round: New Round 👥Investors: Khosla Ventures, Gaingels and Illusian Limbic was founded by Ross Harper (CEO), Sebastiaan de Vries Limbic, their backgrounds include software engineering, #psychology, #machinelearning, and neuroscience. Together, they were scaling #mental healthcare throughout the globe with the help of state-of-the-art AI and gorgeous product design. The startup plans to use the money to increase the number of American #healthcare providers who have access to its clinical mental health AI. Clinical mental #health AI startup Limbic. Ross Harper Johanna Habicht Zsuzsa Hudacsko Keno Jüchems Read more - https://lnkd.in/gy-nYVEn To share your startup story write us on - contact@startuprise.io #limbic #neuroscience #machinelearning #healthtech #mentalhealth #artificialintelligence #funding #startup

NEW: Matter Neuroscience is setting out to find a biomarker for happiness. The biotech startup has been running clinical studies on happiness for the past three years to seek to prevent neurological disease. Now, Matter has raised $26 million from VCs including ARCH Venture Partners and Polaris Partners, Business Insider has learned exclusively. Alongside the raise, Matter is releasing a beta version of its research app to the public. The app helps people capture and reflect on positive moments, understand the molecular basis for their emotions, and use that understanding to shape their future happiness. Reflecting on positive memories is the best way to reliably trigger positive emotions, Matter CEO Axel Bouchon told me. The startup hopes to one day sell its findings to pharma companies. Check out Matter’s pitch deck in Business Insider: https://lnkd.in/eSKDFNmv

Showing the world why University of California, Berkeley is #1 in Entrepreneurship! 🌎 Had a wonderful time helping out and attending Berkeley SkyDeck Batch 18 Demo Day! Here are some of this batch’s startups with awesome founders I got to connect with. I highly encourage you check them out! Deeli AI (Hanson Chou & Wilson Haung) A platform for R&D-focused organizations to discover and acquire game-changing technologies. Jellie AI (Alexander Davtyan) AI-vetted candidate database designed to streamline hiring processes and reduce costs. Taltrics (Alex Marshall) AI solutions to help software service firms grow revenue through automated quoting and optimized pricing. TLR Therapeutics (Stephen J. McCormack, PhD and Alexis Poché): Early-stage biotech company focused on developing Tomaralimab for cancer, tumors, and infectious diseases. And of course, always an absolute pleasure reconnecting with friends and partners at Cal Scott Nisbet; Ekin Günaysu! #innovation #VC #UCBerkeley #MoonShot

📢 Founder Stories University Edition is a collection of fireside chats with leading academic founders backed by the AlbionVC team. Having invested in over 30 university spinouts from the leading UK universities, the series highlights personal stories of those who made the leap from academia to entrepreneurship.  In this episode of our founder stories, Professor Amit Nathwani, CEO NovalGen and a leading global mind in gene therapy research, walks Simon Goldman, Partner AlbionVC, through his academic and business career and what still drives him today. Amit reflects on his journey from academia to entrepreneurship, how his early years as a clinician have influenced his licensing deals with big pharmaceutical companies and later his two spinout companies. “The UCL Technology Fund for me has enabled two of my spinout companies. It’s been extremely important for us and UCL as an environment. I think for me it has been crucial because I could not have done what we've been able to do otherwise.” said Prof. Amit Nathwani, CEO, NovalGen     Watch the full story here: https://lnkd.in/eh2zsEFY UCL Business Ltd #biotech #lifesciences #immunotherapy #cancerresearch #BiotechInnovation #medicalbreakthroughs #tech #uktech #founders #startups #entrepreneurs #venturecapital #founderstories

Make way for Gen Z, the digital natives armed with an innovative mindset are here to change the world. I was inspired by the passion and innovation of aspiring pre-college Gen Z entrepreneurs at the recent Youth Entrepreneurship Summit (YES 2024) organized by iStart Valley, where I was invited to deliver a keynote. Six startups that made it to the finals showed their passion to tackle global challenges through innovations like silicon-based quantum processors (Quantum Fab), carbon-neutral energy for the underserved (Light Ray), AI-driven health diagnostics (Lesion Detector), AI-based music therapy for neurological disorders (NeuroTunes), aircraft safety systems (FRS), and phones as digital reading glasses (Resolve). It is a long list of energetic organizing committee to recognize, guided by experienced Manjunath (MJ). Amazing judges Vida Vidyangi, Shankar Sahai and Deepthi Rao critically analyzed presentations and offered suggestions. #GenZ #Startups #Innovators #entrepreneurship #Technology #QuantumComputing #AIforGood #RenewableEnergy #FutureLeaders #HealthTech #AirSafety #DigitalNatives #MusicTherapy #Neurology #HealthDiagnostics #CarbonNeutral

🚀🧠  You have a great #neuroscience, #mentalhealth, or #sensorydisorders startup project, but you are struggling to get access to the right experts or gather convincing data to secure seed financing?   Brain&Mind is launching its early-stage asset derisking platform to tackle that. It hinges on our profound sector expertise and is designed to provide:   🤝 The right experts for counseling and support, among our 1,500+ top-notch clinical experts and CNS partners    💡 Down-to-earth expertise to qualify vendors, help build your team, navigate the wild rivers of regulation, and prepare for first-in-patient studies 💰 Direct funding for selected projects, ranging from €150K to €300K per project with no strings attached 📌 Want to know more? Don’t hesitate to reach out to the brainmakers Pierre Walrafen and Lila Khennouf, PhD   #StartupProgram #Innovation #NonDilutiveFunding #HealthTech #Entrepreneurship #ResearchSupport #Neurotech

🚀 October Breaks Records in BrainTech Funding! 🧠 The BrainTech sector is experiencing tremendous momentum, with €269M raised across 14 funding rounds in October alone! This field, where neuroscience meets cutting-edge technology, continues to attract significant investments aimed at reshaping mental health, neurology, cognitive performance, and our understanding of the human brain. At Newfund, we closely track these developments through a dedicated review of BrainTech funding rounds across Europe and the United States. Our in-depth coverage helps us stay on top of market trends and identify the key players driving innovation. 🌍 🔍 Key Takeaways: -Significant capital is flowing into BrainTech, highlighting a strong investor appetite for neuroscience-based innovations with large deal like in ShiraTronics, Inc. or INBRAIN Neuroelectronics. -BrainTech startups are well diversified with projects targeting mental health, neurological disorders, cognitive enhancement... -Both established and emerging investors are betting on groundbreaking technologies that could redefine healthcare and human potential.

🚨 MintNeuro funding round announcement 🚨 Parkwalk recently invested in MintNeuro, an Imperial College London spinout and innovative startup at the dynamic intersection of neurotechnology and semiconductors. This capital raise will enable MintNeuro to accelerate delivery of its silicon roadmap and advance clinical deployment of next-generation implantable devices, designed to treat major neurological disorders including epilepsy, Parkinson's and dementia. Martin Glen, Investment Director at Parkwalk, said: “MintNeuro’s innovative technology has the potential to change the lives of millions of patients suffering from a diverse range of neurological conditions. Its accessible, adaptable solution represents a major advancement in treatment options, and we’re extremely excited to be supporting the team in its journey to revolutionise neurological care.” Read the full press release here: https://lnkd.in/eiC7qeJM Parkwalk invested alongside Empirical Ventures, Imperial College London, Plug and Play Tech Center, Excellis and several prominent angel investors. #InvestinginInnovation #spinout #EIS #medtech #neurotechnology

Enlipsium's commitment to innovation and excellence has been recognised by Luminate NY, a leading accelerator program supporting startups in the optics, photonics, and imaging industries. Being chosen among a pool of remarkable startups is a testament to our dedication to improving cancer treatments through better dosimetry systems for radiation therapy. This opportunity is especially significant for us as it marks our entry into the US market. The validation of our product by esteemed industry leaders and experts through Luminate Accelerator NY reaffirms our belief in the transformative potential of our dosimetry systems, especially in the context of high-energy radiation therapy for cancer treatment. We're excited to bring our innovative solutions to the forefront and address the evolving needs of patients and healthcare professionals in the US market. We're eager to leverage Luminate NY's invaluable resources, mentorship, and funding to accelerate our growth trajectory. Collaborating with industry experts, investors, and fellow entrepreneurs will undoubtedly fuel our journey towards success. Together, we'll continue to revolutionise the cancer treatment landscape with cutting-edge technology and make a lasting impact on patient outcomes. NextCorps, Sujatha Ramanujan, Veronica LoCurcio, Damon Diehl. #DeepTech #Innovation #Photonics #Optics #Imaging #Entrepreneurship #TechStartup #EmpireStateDevelopment #AcceleratorProgram #MilestoneAchievement https://lnkd.in/gTJ__ji3